Tryptophan and Nicotinic Acid Metabolism in Bladder Cancer Patients
Author Information
Author(s): E. Quagliariello, F. Tancredi, L. Fedele, C. Saccone
Primary Institution: Institute of Biological Chemistry, University of Naples and Institute of Biological Chemistry, University of Camerino, Italy
Hypothesis
The study investigates the relationship between bladder tumors and the metabolic by-products from tryptophan degradation.
Conclusion
Treatment with nicotinamide reduces the excretion of 3-hydroxyanthranilic acid in bladder cancer patients.
Supporting Evidence
- 3-hydroxyanthranilic acid was present in the urine of 44 out of 47 patients with bladder cancer.
- Treatment with nicotinamide led to a gradual disappearance of 3-hydroxyanthranilic acid in 14 of the 23 treated patients.
- Normal excretion was achieved in only 3 out of 7 patients treated with both nicotinamide and vitamin B6.
Takeaway
Doctors looked at the urine of people with bladder cancer to see how their bodies break down a substance called tryptophan, and found that a vitamin treatment helped change this process.
Methodology
Urine samples from patients were analyzed using chromatography to identify metabolites before and after treatment with nicotinamide and vitamin B6.
Limitations
The study did not find a consistent pattern of metabolites that could definitively correlate with bladder cancer.
Participant Demographics
Patients with cancer of the bladder.
Want to read the original?
Access the complete publication on the publisher's website